- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Uncontrolled severe asthma. Uncontrolled severe allergic asthma. Severe chronic spontaneous urticaria.
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Omalizumab – March 2026
Injection 75 mg in 0.5 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen
Last updated
11 March 2026